1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C, Capranzano P, Gori T, Latib A, Lesiak M, Nef H, Caramanno G, Naber C, Mehilli J, Di Mario C, Sabaté M, Münzel T, Colombo A, Araszkiewicz A, Wiebe J, Geraci S, Jensen C, Mattesini A, Brugaletta S, Capodanno D.
Tamburino C, et al. Among authors: colombo a.
JACC Cardiovasc Interv. 2016 Mar 14;9(5):440-9. doi: 10.1016/j.jcin.2015.10.042. Epub 2016 Jan 6.
JACC Cardiovasc Interv. 2016.
PMID: 26875648
Free article.